DiaGenic seeks microarray partners for breast cancer blood test
This article was originally published in Clinica
Molecular diagnostic company DiaGenic is looking for technological partners for what it says is a novel means of detecting breast cancer from blood samples. The Oslo, Norway firm said its gene-expression testing method could also be applied to other cancers and Alzheimer's disease, for which there is currently no biologic diagnostic.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.